<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048815</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH061758</org_study_id>
    <secondary_id>R01MH061758</secondary_id>
    <secondary_id>R01MH061757</secondary_id>
    <secondary_id>R01MH061394</secondary_id>
    <secondary_id>DSIR AT-SO</secondary_id>
    <nct_id>NCT00048815</nct_id>
    <nct_alias>NCT00043524</nct_alias>
    <nct_alias>NCT00050544</nct_alias>
  </id_info>
  <brief_title>Drug Therapy to Treat Minor Depression</brief_title>
  <official_title>Pharmacotherapy for Minor Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 6-month study will compare the effectiveness of citalopram (CelexaÂ®), hypericum (St.
      John's Wort), and placebo for the treatment of minor depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Minor depression is highly prevalent, causes substantial morbidity and disability, presents a
      serious risk factor for the development of major depressive disorder, yet is under recognized
      and under treated. Researchers have determined that patients with minor depression frequently
      seek treatment from general practitioners and are often treated with prescription
      antidepressants. There is a need to evaluate the effectiveness of St. John's Wort in the
      management of minor depression. If the proposed study demonstrates the efficacy of St. John's
      Wort and/or citalopram, it will suggest treatment paradigms that can be tested and applied in
      primary care settings.

      Subjects participated in a 12-week double-blind randomized study comparing St. John's Wort,
      citalopram, and placebo. Subjects were recruited through clinical referrals and community
      advertising. Data were obtained at the baseline visit (just prior to randomization) and at
      postrandomization visits conducted at 2-week intervals for the next 12 weeks, for a modified
      intent-to-treat sample consisting of all 73 subjects with at least 1 post-randomization visit
      (evaluable sample).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>We expect that subjects with minor depression treated for 12 weeks with St. John's Wort or citalopram will have significantly greater reduction in depressive symptom severity than those treated with placebo. This will be measured by blind ratings on the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) which has a total score range from 0 to 84 with 0 being not depressed at all and 84 being the most depressed. The change will be calculated by subtracting the Week 12 score from the Baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>We expect that subjects treated for Minor Depression for 12 weeks with either St. John's Wort or citalopram will have similar safety profiles to subjects treated with placebo, and will not differ by more than 20% in rates of adverse side effects (e.g., nausea, headache, insomnia, hypersomnia, diarrhea) from subjects treated with placebo. This was measured by the number of adverse events (physical symptoms) emerging or worsening during 12 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>St. John's Wort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Established Selective Serotonin Reuptake Inhibitor antidepressant</description>
    <arm_group_label>citalopram</arm_group_label>
    <other_name>Celexa, Cipramil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>St. John's Wort</intervention_name>
    <description>Natural extract from the St. John's Wort plant.</description>
    <arm_group_label>St. John's Wort</arm_group_label>
    <other_name>Hypericum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minor Depression symptoms for at least 6 months

          -  Endorse one of the DSM-IV &quot;A&quot; criteria for MDD and at least one other symptom of MDD
             or endorse both of the &quot;A&quot; criteria for MDD

          -  Global Assessment of Functioning (GAF) score &lt; 70

          -  Short form health survey (SF-36) social functioning score &lt;= 75% or an emotional role
             functioning score &lt;= 67%

          -  HAM-D-17 score 10-17, inclusive

          -  Minor depression symptoms for at least 6 months

        Exclusion Criteria:

          -  Major depressive disorder (MDD) or dysthymia within the past year or in partial
             remission of MDD

          -  At least a 12-week course of either citalopram at a minimum or 40 mg/day or St. John's
             Wort at a minimum of 900 mg/day during the current episode of depression

          -  Previous intolerance to either citalopram or St. John's Wort or history of nonresponse
             to either citalopram at a minimum of 40 mg/day or St. John's Wort at a minimum of 900
             mg/day for at least 12 weeks

          -  Unstable medical illness, including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurologic, or hematologic disease

          -  Uncontrolled seizure disorder

          -  The following DSM-IV diagnoses: organic mental disorders; substance use disorders,
             including alcohol, active within the last year or patients with a positive urine drug
             screen; schizophrenia; delusional disorder; psychotic disorders not elsewhere
             classified; bipolar disorder; bereavement; adjustment disorder; antisocial personality
             disorder; panic disorder, social phobia, generalized anxiety disorder (GAD), or
             obsessive compulsive disorder (OCD). Patients may have a lifetime diagnosis of an
             anxiety disorder as long as it is not current.

          -  Mood-congruent or mood-incongruent psychotic features

          -  Psychotropic drugs

          -  Hypothyroidism

          -  Investigational psychotropic drugs within the last year

          -  Positive toxicology screen

          -  Medications metabolized by the CYP3A4 system, where induction of this system poses a
             risk to the medical stability of the patient

          -  Pregnancy or refusal to use a medically accepted method of contraception

          -  Serious suicide or homicide risk

          -  Psychotherapy beginning less than 3 months ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A. Nierenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nimh.nih.gov/science-news/2003/treatment-for-minor-depression.shtml</url>
    <description>Click here to view the &quot;Treatment for Minor Depression&quot; NIH news release.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2002</study_first_submitted>
  <study_first_submitted_qc>November 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2002</study_first_posted>
  <results_first_submitted>June 17, 2014</results_first_submitted>
  <results_first_submitted_qc>May 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2018</results_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Andrew A. Nierenberg, MD</investigator_full_name>
    <investigator_title>Director Bipolar Clinic and Research Program</investigator_title>
  </responsible_party>
  <keyword>Minor Depression</keyword>
  <keyword>St. John's Wart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Citalopram</title>
          <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>St. John's Wort</title>
          <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Citalopram</title>
          <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>St. John's Wort</title>
          <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.5"/>
                    <measurement group_id="B2" value="42.2" spread="14.1"/>
                    <measurement group_id="B3" value="51.4" spread="16.6"/>
                    <measurement group_id="B4" value="48.1" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)</title>
        <description>We expect that subjects with minor depression treated for 12 weeks with St. John's Wort or citalopram will have significantly greater reduction in depressive symptom severity than those treated with placebo. This will be measured by blind ratings on the Inventory of Depressive Symptomatology â Clinician Rated (IDS-C) which has a total score range from 0 to 84 with 0 being not depressed at all and 84 being the most depressed. The change will be calculated by subtracting the Week 12 score from the Baseline score.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Citalopram</title>
            <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>St. John's Wort</title>
            <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)</title>
          <description>We expect that subjects with minor depression treated for 12 weeks with St. John's Wort or citalopram will have significantly greater reduction in depressive symptom severity than those treated with placebo. This will be measured by blind ratings on the Inventory of Depressive Symptomatology â Clinician Rated (IDS-C) which has a total score range from 0 to 84 with 0 being not depressed at all and 84 being the most depressed. The change will be calculated by subtracting the Week 12 score from the Baseline score.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.47" spread="1.36"/>
                    <measurement group_id="O2" value="-9.35" spread="1.23"/>
                    <measurement group_id="O3" value="-10.49" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment</title>
        <description>We expect that subjects treated for Minor Depression for 12 weeks with either St. Johnâs Wort or citalopram will have similar safety profiles to subjects treated with placebo, and will not differ by more than 20% in rates of adverse side effects (e.g., nausea, headache, insomnia, hypersomnia, diarrhea) from subjects treated with placebo. This was measured by the number of adverse events (physical symptoms) emerging or worsening during 12 weeks of treatment.</description>
        <time_frame>Change from Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Citalopram</title>
            <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>St. John's Wort</title>
            <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment</title>
          <description>We expect that subjects treated for Minor Depression for 12 weeks with either St. Johnâs Wort or citalopram will have similar safety profiles to subjects treated with placebo, and will not differ by more than 20% in rates of adverse side effects (e.g., nausea, headache, insomnia, hypersomnia, diarrhea) from subjects treated with placebo. This was measured by the number of adverse events (physical symptoms) emerging or worsening during 12 weeks of treatment.</description>
          <units>Number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="4.4"/>
                    <measurement group_id="O2" value="5.0" spread="4.5"/>
                    <measurement group_id="O3" value="3.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>The Patient-Rated Inventory of Side Effects (PRISE; Rush et al., 2004) was administered at baseline and all subsequent visits. This obtained information not only about the presence or absence of 32 specific adverse events (and the opportunity to write in âothersâ), but whether those were present at a tolerable or distressing level or constituted a serious adverse event. Vital signs and medication compliance were also assessed at each visit during treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Citalopram</title>
          <description>Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>St. John's Wort</title>
          <description>Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>PRISE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness on standing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Poor coordination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sleeping too much</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Poor concentration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>General malaise</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased energy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Menstrual irregularity (females)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of sexual desire</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Trouble achieving orgasm</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Trouble with erections (male)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Increased perspiration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Stringent inclusion criteria may have yielded a sample who depression was too mild to show added benefit for either active treatment beyond general therapeutic effects of study participation</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Hyman Rapaport, M.D.</name_or_title>
      <organization>Cedars Sinai Medical Center</organization>
      <phone>310-423-2600</phone>
      <email>mark.rapaport@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

